Christopher Paul German - 12 Aug 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Corporate Controller & CAO
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German
Issuer symbol
RYTM
Transactions as of
12 Aug 2025
Net transactions value
-$99,915
Form type
4
Filing time
14 Aug 2025, 18:47:35 UTC
Previous filing
11 Jul 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
German Christopher Paul Corporate Controller & CAO 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German 14 Aug 2025 0001260835

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $17,970 +1,000 +108% $17.97 1,922 12 Aug 2025 Direct
transaction RYTM Common Stock Options Exercise $24,615 +500 +54% $49.23 1,422 12 Aug 2025 Direct
transaction RYTM Common Stock Sale $142,500 -1,500 -62% $95.00 922 12 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Options (Right to Buy) Options Exercise $0 -1,000 -16% $0.000000 5,231 12 Aug 2025 Common Stock 1,000 $17.97 Direct F2
transaction RYTM Stock Options (Right to Buy) Options Exercise $0 -500 -11% $0.000000 4,050 12 Aug 2025 Common Stock 500 $49.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025.
F2 The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.
F3 The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.